Antibiotic promise in superbug war

June 22, 2018, Flinders University
Dr Ramiz Boulos. Credit: Flinders University

An entirely new class of antibiotics has been shown to be effective against 100 different samples of Clostridium difficile, often the cause of drug-resistant infections picked up by patients while in hospital.

The new antibiotic developed in Australia, called Ramizol, was shown to be effective even against C. difficile which has developed resistant to other currently-available .

A scientific paper published in the journal Diagnostic Microbiology and Infectious Disease (Elsevier), has shown Ramizol, a first-in-class stilbene-based investigational antibiotic for the treatment of Clostridium difficile (CDI), is effective against 100 clinical isolates of C. difficile.

The paper, entitled "Comparison of the in vitro antibacterial activity of Ramizol, fidaxomicin, vancomycin and metronidazole against 100 clinical isolates of Clostridium difficile by broth microdilution," has shown resistance emergence against vancomycin and metronidazole.

The results have shown that vancomycin-resistant isolates are more than 250 times less susceptible (MIC > 8 μg/mL) to fidaxomicin compared to fidaxomin-sensitive strains (MIC90 = 0.03 μg/mL).

The research, which was undertaken jointly by Boulos & Cooper Pharmaceuticals, US-based Micromyx LLC and Flinders University, has shown there is no apparent impact of ribotype, toxin-production, or resistance to fidaxomicin, vancomycin or metronidazole on the activity of Ramizol.

Credit: Flinders University

CEO and founder of Boulos & Cooper Pharmaceuticals, Dr. Ramiz Boulos, says: "C. difficile strains showing resistance to both vancomycin and fidaxomicin is an unexpected finding, given these two antibiotics have different mechanisms of action."

"The emergence of resistance against the only three antibiotics currently used for treating CDI is alarming, highlighting the need for novel, safe and effective antibiotics," he says.

"We believe Ramizol has the potential to be the standard of care for treating CDI and has the potential to be a blockbuster drug," says Dr. Boulos, an adjunct lecturer at the College of Science and Engineering at Flinders University.

Dr. Boulos, who became an SA Tall Poppy of science in 2014 while working on his patented antimicrobials and other projects at the Flinders University Institute of NanoScale Science and Technology in 2013-2014, is now based in Perth where he obtained his Ph.D. in Chemistry from the University of Western Australia in 2011.

Flinders University College of Medicine and Public Health Professor Ross McKinnon and College of Science and Engineering Professor Colin Raston are advisers of Boulos & Cooper Pharmaceuticals.

In the US alone, Dr. Boulos says at least 250,000 people per year are affected by CDI, gonorrhoea and some Gram-negative bacteria every year. With few treatment options and rising antibiotic resistance for these three bacteria, the US Department of Health and Human Services' Centers for Disease Control and Prevention has classified them as "urgent-level" – its highest category of threat level – declaring each of them "an immediate that requires urgent and aggressive attention."

Explore further: New compound shown to be as effective as FDA-approved drugs against life-threatening infections

More information: Cindy Wolfe et al. Comparison of the in vitro antibacterial activity of Ramizol, fidaxomicin, vancomycin and metronidazole against 100 clinical isolates of Clostridium difficile by broth microdilution, Diagnostic Microbiology and Infectious Disease (2018). DOI: 10.1016/j.diagmicrobio.2018.06.002

Related Stories

New compound shown to be as effective as FDA-approved drugs against life-threatening infections

June 15, 2018
Purdue University researchers have identified  a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the Food and Drug Administration to treat life-threatening infections ...

Metabolite therapy proves effective in treating C. difficile in mice

March 20, 2018
A team of UCLA researchers found that a metabolite therapy was effective in mice for treating a serious infection of the colon known as Clostridium difficile infection, or C. difficile.

Supercharged antibiotics could turn tide against superbugs

January 5, 2018
An old drug supercharged by University of Queensland researchers has emerged as a new antibiotic that could destroy some of the world's most dangerous superbugs.

Can probiotics reduce the severity of C. difficile infections?

August 7, 2014
Probiotics have shown promise for treating patients with recurrent Clostridium difficile infections. However, their safety and quality control requires further study – especially in immunocompromised patients, concludes ...

Researchers define target and mechanism of antibacterial drug fidaxomicin (Dificid)

March 29, 2018
A team of Rutgers University and international scientists has determined the molecular target and mechanism of the antibacterial drug fidaxomicin (trade name Dificid).

Recommended for you

Deadly Rift Valley fever: New insight, and hope for the future

July 19, 2018
Health control measures alone could be ineffective in the long term fight against the deadly Rift Valley fever which affects both humans and animals, a new study in the journal PNAS reports.

Yeast species used in food industry causes disease in humans

July 19, 2018
A major cause of drug-resistant clinical yeast infections is the same species previously regarded as non-pathogenic and commonly used in the biotechnology and food industries. The study, published on July 19th in the open-access ...

New guidelines to diagnose, manage rare endocrine disorders

July 19, 2018
International guidelines have been published for the first time to help doctors around the globe diagnose and manage patients with a very rare set of endocrine diseases known as pseudohypoparathyroidism and its related disorders, ...

Overuse of antibiotics not what the doctor ordered

July 19, 2018
With increased use of antibiotics worldwide linked to growing antibiotic resistance, a world-first study co-authored by a QUT researcher has highlighted the growing impact of non-prescription supply of antibiotics in community ...

Alcohol-related cirrhosis deaths skyrocket in young adults

July 18, 2018
Deaths from cirrhosis rose in all but one state between 1999-2016, with increases seen most often among young adults, a new study shows.

Childhood abuse linked to greater risk of endometriosis, study finds

July 17, 2018
Endometriosis, a painful condition that affects one in 10 reproductive-age women in the U.S., has been linked to childhood physical and sexual abuse, according to findings published today in the journal Human Reproduction.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.